News Forum: Magnesium sulphate in the treatment of pre-eclampsia

GPs with an interest in women's health review the latest papers of significance from research teams across the world

Magpie Trial Follow-Up Study Collaborative Group BJOG 2007; 114 (3): 289-99 doi:10.1111/j.1471-0528.2006.01165.x.

In this large multicentre trial, 4,483 children were followed up to 18 months of age from a randomised trial of magnesium sulphate versus placebo in pregnancy for pre-eclampsia, to look at morbidity, mortality and neurodevelopment of the children exposed to magnesium in utero.

Magnesium sulphate is used worldwide for seizure therapy and prophylaxis in women with eclampsia and pre-eclampsia. Magnesium may act by opposing calcium-dependent arterial constriction and may also antagonize the increase in intracellular calcium concentration.

This is the first well-designed trial with enough children to look at the long-term consequences for the child of treating the mother with magnesium.

This group published the data on the women themselves in BJOG the month before this study and showed that the reduction in the risk of eclampsia following prophylaxis with magnesium sulphate was not associated with an excess of death or disability for the women after two years.

It also reminds us how serious eclampsia is: 58 of 1,650 (3.5 per cent) women allocated magnesium sulphate died or had serious morbidity potentially related to pre-eclampsia, compared with 72 of 1,725 (4.2 per cent) women allocated placebo (RR 0.84, 95% CI 0.60-1.18).

In the children exposed in utero to magnesium, 245 of 1,635 (15.0 per cent) were dead or had neurosensory disability at 18 months, compared with 233 of 1,648 (14.1 per cent) allocated placebo (RR 1.06, 95% CI 0.90-1.25), and of survivors, 19 of 1,409 (1.3 per cent) had neurosensory disability at 18 months, compared with 27 of 1,442 (1.9 per cent; RR 0.72, 95% CI 0.40-1.29).

The conclusion is that exposure to magnesium in utero gives no significant difference in death rates or disabilities for the child, at least up to 18 months of age. This is very reassuring for clinicians and patients alike.

- Dr Sally Hope is a GP in Woodstock, Oxfordshire, and honorary research fellow in women's health, department of primary health care, University of Oxford.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases